ID   SV-BR-1
AC   CVCL_4U12
SY   SV-BR1
DR   Wikidata; Q54970928
RX   Patent=US7674456;
RX   PubMed=16958969;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7812.
CC   Characteristics: ER/PR-negative and ERBB2-positive.
CC   Doubling time: 48 hours (Patent=US7674456).
CC   Derived from site: Metastatic; Chest wall; UBERON=UBERON_0016435.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 02-05-24; Version: 8
//
RX   Patent=US7674456;
RA   Wiseman C.L., Kharazi A.;
RT   "Breast cancer cell lines and uses thereof.";
RL   Patent number US7674456, 09-Mar-2010.
//
RX   PubMed=16958969; DOI=10.1111/j.1075-122X.2006.00319.x;
RA   Wiseman C.L., Kharazi A.;
RT   "Objective clinical regression of metastatic breast cancer in
RT   disparate sites after use of whole-cell vaccine genetically modified
RT   to release sargramostim.";
RL   Breast J. 12:475-480(2006).
//